Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05770947
Other study ID # 2000033150
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 24, 2023
Est. completion date December 31, 2024

Study information

Verified date April 2024
Source Yale University
Contact Janet A Lydecker, PhD
Phone 203-785-7210
Email janet.lydecker@yale.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will test the feasibility and acceptability of two treatments for adolescents with higher weight seeking treatment for bulimia nervosa (binge eating and purging, or going to extremes to lose weight).


Description:

This study will test the feasibility and acceptability of two treatments for adolescents with higher weight seeking treatment for bulimia nervosa. Bulimia nervosa is when individuals binge eat (overeat while feeling like they lost control) and purge (do something extreme or unhealthy to lose weight or prevent weight gain). Bulimia nervosa happens across different ages and body sizes. This study is focusing on adolescents who have a larger body size. Adolescents will receive treatment that is 4 months of 45-minute sessions, weekly. Treatment will occur over telehealth (e.g., zoom), and the whole study is online.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 12 Years to 19 Years
Eligibility Inclusion Criteria: - Have higher weight (>85th BMI percentile or >85th percentile in past year) - 2 binge/purge episodes per month for the prior 3 months - Be otherwise-healthy youth (i.e., no uncontrolled or serious medical conditions); - Read, comprehend, and write English at a sufficient level to complete study-related materials; - Provide an approval form from a healthcare provider; - Provide a signed and dated written assent (or consent for youth age 18 or 19) prior to study participation; - Provide a signed and dated written consent from one parent prior to study participation; - Be available for participation in the study for 4 months. Exclusion Criteria: - Medical or psychiatric conditions requiring hospitalization or intensive care - anorexia nervosa - developmental or cognitive disorders that would interfere with therapy - pregnancy or breastfeeding - concurrent treatments (medication or psychological) influencing appetite or weight - began hormone therapy in prior 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cognitive Behavioral Therapy
Cognitive Behavioral Therapy (CBT) is a psychological treatment or "talk therapy" that integrates how people think, feel, and behave to create new behavior patterns that improve thinking processes and reduce distress.
Mindfulness
Mindfulness is a psychological treatment or "talk therapy" that practices different coping skills to improve thinking processes and reduce distress.

Locations

Country Name City State
United States Yale University (Teen Power - Online) New Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University National Eating Disorders Association

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Bulimia nervosa remission assessed by the Eating Disorder Examination Questionnaire (EDE-Q) Remission from binge eating and purging behaviors will be assessed by EDE-Q. The EDE-Q is a self-report questionnaire with four subscales and a global severity score. the global score ranges from 0-6 with higher scores reflecting greater severity of eating disorder behaviors. baseline and post-treatment (Month 4)
Secondary Change in Binge eating frequency assessed by the EDE-Q Number of episodes of binge eating in past month baseline and post-treatment (Month 4)
Secondary Change in Purging frequency assessed by the EDE-Q Number of episodes of purging in past month baseline and post-treatment (Month 4)
Secondary Change in eating disorder psychopathology assessed by the Eating Disorder Examination Questionnaire (EDE-Q) global score. Eating disorder psychopathology will be assessed using the EDE-Q global score. The EDE-Q is a self-report questionnaire with four subscales and a global severity score. the global score ranges from 0-6 with higher scores reflecting greater severity of eating disorder psychopathology. baseline and post-treatment (Month 4)
Secondary Change in Depression assessed using Patient Health Questionnaire-9 (PHQ-9) Depression will be assessed using the PHQ-9. PHQ-9 is a validated questionnaire used to screen for depression with a range of scores from 0-27. Higher scores indicate more severe depressive symptoms. baseline and post-treatment (Month 4)
Secondary Change in Self-esteem assessed using the Rosenberg Self-Esteem Scale (RSES) Self-esteem will be assessed using the RSES. The RSES is a self-report measure that consists of 10 statements related to overall feelings of self-worth or self-acceptance. The items are answered on a four-point scale ranging from strongly agree to strongly disagree. The total score ranges from 0 to 30 with higher scores indicating higher self esteem. baseline and post-treatment (Month 4)
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04174703 - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing N/A
Terminated NCT04278755 - Binge Eating & Birth Control Phase 2
Withdrawn NCT02978742 - Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder N/A
Withdrawn NCT00988481 - Topiramate Augmentation in Bulimia Nervosa Partial Responders Phase 4
Completed NCT00184301 - A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder. N/A
Completed NCT00522769 - Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents Phase 1/Phase 2
Completed NCT00304187 - Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa Phase 2
Recruiting NCT04409457 - Self-Control in Bulimia Nervosa N/A
Recruiting NCT05509257 - Naltrexone Neuroimaging in Teens With Eating Disorders Early Phase 1
Recruiting NCT05862389 - Study on the Mechanism of Eating Disorder
Recruiting NCT05937243 - Identifying Effective Technological-based Augmentations to Enhance Outcomes From Self-help Cognitive Behavior Therapy for Binge Eating N/A
Recruiting NCT05728021 - Smartphone-based Aftercare for Inpatients With Bulimia Nervosa N/A
Completed NCT03781921 - The Neural Bases of Emotion Regulation in Bulimia Nervosa
Completed NCT02553824 - FDA Approved Medication to Reduce Binge Eating and/or Purging Phase 1
Terminated NCT04041024 - Decision-making and Risk-taking in Bulimia N/A
Completed NCT04265131 - Emotion Regulation in Eating Disorders: How Can Art Therapy Contribute to Treatment Outcome? N/A
Recruiting NCT06431854 - Evaluation of a New Treatment Program for Adolescents With Eating Disorders: MINERVA Program N/A
Recruiting NCT02960152 - Periodontal Impact of Eating Disorders (the PERIOED Study) N/A
Completed NCT00916071 - Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders N/A
Terminated NCT00308776 - Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa N/A